Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Misti Paul and Helen Ansell
  • August 7, 2019
  • Articles

Integrating data

Integrating data

How to conduct an effective epidemiological data review

Clients often ask us if we can triangulate various data sources to fully understand the opportunity for an asset. There are clear benefits - combining primary market research findings with existing data sets provides validity and depth, whilst eliminating many inconsistencies, which helps guide the direction for future marketing strategy and initiatives. 

read more »

How patient insights were brought to life with graphic novel outputs

How patient insights were brought to life with graphic novel outputs

Our client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks. Their new product promised greater freedom from these acute attacks and therefore from the associated burden. The challenge was to understand why many patients remain on older therapy types and how the pathway to more modern therapy options, with better efficacy and side effect profiles, could be mapped out for physicians and patients. Our client further requested that insights from the research were brought to life in the insights workshop meeting in a new and impactful way.
 

read more »

How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment

How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment

Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.

read more »

How we used behavioural economic theory to reveal fresh insights into patient compliance

How we used behavioural economic theory to reveal fresh insights into patient compliance

Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.

However, sales data suggests that repeat prescriptions drastically reduce after the first 3-6 months. Although the product has a known SE profile, our client believes that this can be well managed and controlled. 

read more »

How we assessed the opportunity for a rare disease product in emerging markets

How we assessed the opportunity for a rare disease product in emerging markets

Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.

read more »